A son of glembatumumab vedotin has just started its phase 1 study.
ApexOnco Front Page
Recent articles
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
The project has priority review, but deaths could raise eyebrows.
An in vivo Car-T produced a 100% response rate – in three patients.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Arcellx and AstraZeneca take centre stage.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
